uniQure plunges after additional Huntington's disease study data

uniQure plunges after additional Huntington's disease study data: the analysis positions PTC, WVE and PTCT to benefit and QURE, TSHA and PASG under pressure; confidence high.

Analyzed 2026-09-30 — point-in-time, never revised. Outcomes are scored against SPY and published either way.

Ranked exposures

▼ QURE uniQure — impact -95 · confidence high · horizon immediate · 1st order
Missed long-term efficacy significance weakens AMT-130's approval path and forces costly confirmatory trials.
Chain: additional Phase I/II data released for AMT-130 → long-term efficacy significance falls short of expectations → regulatory path to accelerated approval becomes uncertain → confirmatory trial spending and launch delay rise
What would break the call: FDA accepts the filing on existing data and grants approval, restoring the near-term revenue timeline.
▲ PTC PTC Therapeutics — impact +72 · confidence low · horizon immediate · 2nd order
PTC advances oral votoplam for Huntington's against a thinner field, raising odds of partner milestones and future royalty revenue.
Chain: lead gene therapy competitor stumbles on durability → Huntington competitive field thins for oral agents → votoplam gains relative share of future market → partner milestone and royalty expectations increase
What would break the call: Votoplam pivotal data show insufficient huntingtin lowering or liver safety signals, erasing the competitive gain.
▼ TSHA Taysha Gene Therapies — impact -58 · confidence low · horizon immediate · 2nd order
Taysha depends on intrathecal AAV dosing for Rett syndrome, so doubts about durable neurologic benefit raise capital costs.
Chain: intrathecal AAV durability questioned across CNS programs → investors apply larger discount to similar platforms → equity issuance prices lower for Taysha → cost of capital for Rett program rises
What would break the call: Taysha reports durable Rett efficacy data or closes a large partnership, decoupling it from uniQure sentiment.
▼ PASG Passage Bio — impact -55 · confidence low · horizon weeks · 2nd order
Passage Bio uses brain-directed AAV delivery, making equity funding scarcer and more dilutive after this high-profile durability setback.
Chain: brain-directed AAV benefit durability doubted → generalist funds reduce gene therapy allocations → Passage Bio financing terms turn more dilutive → clinical spend pace slows
What would break the call: Passage Bio announces positive frontotemporal dementia data or a funded partnership, restoring independent valuation support.
▲ WVE Wave — impact +51 · confidence medium · horizon immediate · 2nd order
Weakened competing Huntington therapies improve Wave's antisense partnering leverage and revenue prospects.
Chain: gene therapy option for Huntington looks weaker → antisense approaches gain relative standing → Wave partnering leverage on WVE-003 improves → future milestone and royalty terms strengthen
What would break the call: Wave reports weak huntingtin lowering or tolerability problems in its Huntington cohort readout.
▲ PTCT PTC — impact +50 · confidence low · horizon weeks · 2nd order
PTC Therapeutics development pipeline gains value after uniQure study data eliminates a key Huntington competitor.
Chain: AMT-130 durability signal disappoints investors → Huntington disease-modifying field narrows → PTC oral program value weighting increases → pipeline valuation and partner economics improve
What would break the call: Regulators approve AMT-130 anyway, returning a one-time therapy to the competitive set.
▼ SRPT Sarepta — impact -45 · confidence high · horizon immediate · 2nd order
Negative gene therapy sentiment raises Sarepta's financing costs as investors question AAV durability.
Chain: investors question long-term AAV transgene expression → AAV sector multiples compress broadly → Sarepta debt and equity financing cost rises → pipeline discount rate increases
What would break the call: Sarepta posts strong Elevidys revenue and durability data, separating its story from platform sentiment.
▼ CLPT ClearPoint Neuro — impact -42 · confidence low · horizon quarters · 2nd order
ClearPoint Neuro risks lower procedure revenue because fewer AMT-130 commercial infusions would use its navigation platform.
Chain: AMT-130 commercial launch odds fall → fewer stereotactic brain infusions forecast → ClearPoint navigation and disposable revenue outlook trimmed → biologics services segment growth slows
What would break the call: ClearPoint guides higher on functional neurosurgery cases or announces new delivery partners offsetting AMT-130 volume.
▼ LXEO Lexeo Therapeutics — impact -42 · confidence low · horizon weeks · 2nd order
Lexeo develops AAV therapies for cardiac and neurologic disease, and harsher scrutiny of long-term benefit delays its financings.
Chain: AAV durability scrutiny intensifies after readout → cardiac and neurologic AAV programs face tougher diligence → Lexeo financing window narrows → trial funding cost rises
What would break the call: Lexeo reports positive Friedreich cardiomyopathy data or secures non-dilutive financing, breaking the sentiment link.
▼ CRSP CRISPR — impact -40 · confidence low · horizon immediate · 3rd order
CRISPR Therapeutics partnership deals decrease after uniQure study data reduces overall confidence in genetic medicines.
Chain: gene therapy durability doubt spreads to genetic medicines → partner appetite for platform deals cools → CRISPR collaboration revenue timing slips → valuation multiple on pipeline compresses
What would break the call: Casgevy patient starts accelerate or a large pharma deal is signed, decoupling CRISPR from AAV sentiment.
▼ SLDB Solid Biosciences — impact -40 · confidence low · horizon weeks · 2nd order
Solid Biosciences funds trials through equity issuance, so a sector-wide derating of gene therapy increases dilution per dollar raised.
Chain: AAV sector valuations reset lower → Solid Biosciences equity price declines → planned raises deliver fewer dollars per share → Duchenne program spending capacity narrows
What would break the call: Solid reports strong microdystrophin expression and functional data, supporting its shares independent of sector sentiment.
▼ VYGR Voyager — impact -39 · confidence medium · horizon weeks · 3rd order
Lower sector investment slows Voyager's AAV licensing activity and reduces research spending efficiency.
Chain: AAV capsid demand tied to partner program funding → partners slow new AAV program starts → Voyager licensing and option fee revenue slips → research collaboration revenue growth decelerates
What would break the call: A major pharma signs a new capsid license with upfront payment, proving demand persists.
▼ RCKT Rocket Pharmaceuticals — impact -35 · confidence low · horizon weeks · 2nd order
Rocket relies on investor appetite for gene therapy to fund late-stage programs, and that appetite narrows after this readout.
Chain: investor appetite for gene therapy narrows → Rocket faces higher cost of equity → late-stage AAV and lentiviral funding tightens → program timelines and spend adjust
What would break the call: Rocket secures approval or a partnership with upfront cash, removing the financing overhang.
▲ IONS Ionis — impact +32 · confidence medium · horizon weeks · 2nd order
Reduced prospects for competing Huntington therapies increase Ionis's antisense asset value and investor attention.
Chain: one-shot Huntington gene therapy credibility weakens → repeat-dosed antisense approaches gain relative standing → Ionis CNS pipeline value weighting rises → partner royalty expectations improve
What would break the call: An antisense Huntington program fails on safety or efficacy, undercutting the modality preference.
▼ RARE Ultragenyx — impact -28 · confidence low · horizon quarters · 2nd order
Ultragenyx carries several AAV assets, so lower confidence in sustained transgene expression compresses the value assigned to that pipeline.
Chain: sustained transgene expression assumptions questioned → AAV asset valuations discounted sector wide → Ultragenyx AAV pipeline value compresses → financing and partnering terms soften
What would break the call: Ultragenyx wins approval for GTX-102 or UX111, restoring credibility to its genetic medicine pipeline.
▼ RGNX Regenxbio — impact -27 · confidence medium · horizon immediate · 2nd order
Disappointing neurological efficacy data weaken AAV platform valuations as partners defer licensed gene therapy spending.
Chain: AAV platform durability questioned after CNS readout → licensees defer new program starts and milestones → Regenxbio royalty and license revenue timing slips → platform valuation compresses
What would break the call: Regenxbio announces a new capsid license with upfront cash or an approval for RGX-121.
▲ NBIX Neurocrine — impact +26 · confidence high · horizon quarters · 2nd order
Continued reliance on symptomatic care sustains Ingrezza demand among Huntington's disease patients with chorea.
Chain: disease-modifying Huntington therapy delayed → patients stay on symptomatic chorea treatment longer → Ingrezza Huntington chorea prescriptions persist → product revenue duration extends
What would break the call: AMT-130 wins accelerated approval, shrinking the long-term symptomatic treatment pool.
▲ TEVA Teva — impact +26 · confidence medium · horizon quarters · 2nd order
Delayed disease-modifying competition extends Austedo XR treatment duration and sustains Huntington's chorea prescription volumes.
Chain: gene therapy approval path for Huntington uncertain → chorea patients remain on symptomatic therapy → Austedo XR prescription volumes hold longer → branded generics growth engine sustained
What would break the call: AMT-130 or a rival disease-modifying drug reaches approval and displaces chronic chorea therapy.
▲ DNLI Denali Therapeutics — impact +22 · confidence low · horizon weeks · 3rd order
Investors favor brain delivery of repeat-dosed enzymes and oligonucleotides when one-time AAV durability looks questionable.
Chain: one-time AAV CNS durability doubted → repeat-dosed brain delivery gains investor preference → Denali transport vehicle platform value rises → partnering and financing terms improve
What would break the call: Denali reports a clinical setback in its lead Hunter syndrome or ALS program.
▼ BEAM Beam Therapeutics — impact -20 · confidence low · horizon weeks · 3rd order
Base editing valuations track genetic medicine sentiment, so a durability setback raises Beam's cost of equity capital.
Chain: genetic medicine sentiment deteriorates broadly → generalist investors reduce sector allocations → Beam equity multiple compresses → future financing becomes more dilutive
What would break the call: Beam posts strong sickle cell editing data or a large partnership, restoring independent valuation.
▲ NVS Novartis — impact +18 · confidence low · horizon quarters · 3rd order
Novartis holds rights to a competing oral Huntington's drug, and weaker gene therapy rivalry improves its eventual pricing power.
Chain: gene therapy competitor in Huntington weakens → Novartis oral huntingtin lowering asset gains standing → future pricing and share assumptions improve → neuroscience pipeline value rises modestly
What would break the call: Novartis discontinues its Huntington program on safety grounds, removing the competitive benefit.
▲ ALNY Alnylam — impact +15 · confidence low · horizon weeks · 3rd order
Alnylam benefits as capital rotates from one-shot gene therapy toward repeat-dosed silencing platforms with clearer durability evidence.
Chain: one-shot gene therapy durability questioned → capital rotates toward repeat-dosed silencing platforms → Alnylam multiple expands on durability evidence → RNAi partner and pipeline value rises
What would break the call: An siRNA safety or durability setback in a major program reverses the modality preference.
▼ CRL Charles River Laboratories — impact -12 · confidence low · horizon quarters · 3rd order
Gene therapy sponsors cutting program starts reduce preclinical study bookings and safety assessment revenue at Charles River.
Chain: AAV sector financing tightens after readout → biotech clients trim preclinical program starts → Charles River safety assessment bookings soften → discovery and safety segment revenue growth slows
What would break the call: Charles River raises guidance on pharma demand, showing gene therapy exposure is immaterial.

Sources

What happened

Horizon	Verdict	Top pick	Excess vs SPY
1 trading days	Mixed	PTC	+2.2% vs SPY
5 trading days	Right	PTC	+38.4% vs SPY

Related scenarios

Stocks in this scenario

QURE · PTC · TSHA · PASG · WVE · PTCT · SRPT · CLPT · LXEO · CRSP · SLDB · VYGR · RCKT · IONS · RARE · RGNX · NBIX · TEVA · DNLI · BEAM · NVS · ALNY · CRL

News events · All scenarios · Pricing · Track record · Methodology · Map your own scenario